Clinical Trial Update: An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

An exploratory, multi-cohort Phase II trial evaluating the combination of AK104 and AK112 for recurrent ovarian cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• AK112

Snippet

Sponsor: Akeso | Conditions: Recurrent Ovarian Cancer | Phase 2 | Status: RECRUITING